Latest News

BioIVT Expands its Support of the Annual North American ISSX Meeting; Highlights Advances in Drug Metabolism and Toxicology Research

BioIVT is sponsoring two symposia, giving several presentations, and exhibiting at this year's conference

WESTBURY, NY - Sep 21, 2017 - BioIVT, a leading provider of biospecimens and related services, today announced that it is increasing its support of the annual North American International Society for the Study of Xenobiotics (ISSX) Meeting. BioIVT will be sponsoring two symposia, giving several presentations, and exhibiting at this year’s conference. This event will be held from Sept. 24-28 at the Rhode Island Convention Center in Providence, RI.

“ISSX North America has always been an important conference for BioIVT, but after our acquisition of Qualyst Transporter Solutions earlier this month, our focus on this market has intensified,” said BioIVT Chief Executive Officer Jeffrey Gatz. “We will be highlighting the successful use of primary hepatocytes as an in vitro model to predict drug ADME behavior in the human liver. The models can be used to predict compound clearance, metabolism, drug-drug interactions, and toxicity in the liver. We will also be showcasing work done with the C-DILI™ Assay, a novel in vitro method to evaluate a compound’s potential for cholestatic drug-induced liver injury (DILI).”

DILI is the most frequently cited reason for withdrawing medications from the marketplace.1 It accounts for approximately 10 percent of all cases of acute hepatitis, and it is the most common cause of acute liver failure in the United States.1

BioIVT’s contributions to this year’s North American ISSX Meeting are outlined below:

Symposia 
Monday, Sept. 25
7:45-8:45 a.m. ET
      • In Vitro Prediction of Drug Metabolism and Transport Using Primary Human Hepatocytes
            o Dr. Hongbing Wang, Professor and Program Chair, Experimental and Translational Therapeutics, Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy
      • Registration: http://www.bioreclamationivtmail.com/page.php?h=c9e18316&id=24725

Tuesday, Sept. 26
6-10 p.m. ET
13th North American Hepatocyte Research Association Meeting
      • Common Mechanisms of DILI and Emerging In Vitro Platforms to Evaluate Them
            o Terry Van Vleet, PhD, Abbvie

      • Quantitative Systems Toxicology and DILI: Where Do Culture Models Fit In?
            o Paul Watkins, PhD, UNC, School of Pharmacy, Medicine, and Public Health

      • Integrating Inhibition and Gene Regulation to Predict DILI: A New Assay for Assessing Cholestasis
            o Christopher Black, PhD, BioIVT (formerly Qualyst)

      • Registration: www.eventbrite.com/e/13th-hepatocyte-research-association-tickets-36933052755

Posters
Wednesday, Sept. 26
1-2 p.m. ET
      • P155 - A New Mechanism-based Human In Vitro Screen (C-DILI™ Assay) for Prediction of Cholestatic Liver Toxicity
            o Kenneth Brouwer, Jonathan Jackson, Kimberly Freeman, Robert St. Claire III, Matthew Palmer and Christopher Black

      • P157 - A Structural Activity Relationship Strategy to Mitigate Cholestatic Hepatoxicity Liabilities Utilizing The C-DILI™ Assay
            o Jonathan Jackson, Kimberly Freeman, Matthew Palmer, Christopher Black, Robert St. Claire III, and Kenneth Brouwer

Thursday, Sept. 27
1-2 p.m. ET
      • P174 - Effects of Incubation Buffer Conditions on In Vitro Primary Cryopreserved Hepatocyte Phase I and Phase II Metabolism
            o Scott Heyward and Philip McCauley

Interested parties can learn more about this meeting at http://www.issx2017na.com .

Reference
1.  https://www.uptodate.com/contents/drug-induced-liver-injury

About BioIVT
BioIVT, formerly known as BioreclamationIVT, is a worldwide provider of biological products to the life sciences and pharmaceutical industries. The company specializes in control and disease-state matrices manufactured from human and animal biological specimens and has recently expanded its offering to include cell processing and phenotypic screening services. As a premier supplier of ADME-toxicology model systems, BioIVT enables scientists and biomedical researchers to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. BioIVT’s reputation for providing exceptional customer service coupled with the highest quality specimens and services have made it the first-choice supplier for biospecimens for more than 35 years. For more information, please visit www.bioreclamationivt.com or follow the company on Twitter @BiorecIVT.